Related Experiment Video
Updated: Jun 4, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Hematogones are markedly decreased in chronic myeloid leukemia: multiparametric flow cytometric analysis
Kar Fai Chow1, Deborah W Sevilla, Adriana I Colovai
1Department of Pathology and Cell Biology, Columbia University Medical Center and the New York Presbyterian Hospital, New York, NY, USA.
Insights
Hematogones, a type of immune cell, are significantly decreased in patients with chronic myeloid leukemia (CML). This reduction was observed at diagnosis and after treatment, suggesting a potential link between CML and immune cell dysregulation.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Previous research indicates reduced hematogones in myelodysplastic syndromes and aplastic anemia.
- Hematogones are immature B lymphocytes crucial for immune function.
Purpose of the Study:
- To investigate the frequency of hematogones in patients with chronic myeloid leukemia (CML).
- To compare hematogone levels in CML patients with age-matched controls.
- To explore potential associations between CML, hematogones, and natural killer cells.
Main Methods:
- Bone marrow samples from 33 CML patients and 50 age-matched controls were analyzed.
- Flow cytometry was used to quantify total and stage I hematogones.
- Natural killer cell counts were also assessed in CML patients at diagnosis.
Main Results:
- CML patients exhibited significantly lower percentages of total and stage I hematogones compared to controls.
- This decrease was evident both at diagnosis and during follow-up post-therapy.
- A significant reduction in natural killer cells was also observed in CML patients at diagnosis.
Conclusions:
- The study demonstrates a significant decrease in hematogones in chronic myeloid leukemia patients.
- Further research is needed to understand the mechanisms behind this hematogone reduction in CML.
- The findings may have implications for understanding immune alterations in other myeloproliferative neoplasms.
Abstract:
Past studies have shown decreased hematogones in the bone marrow of patients with myelodysplastic syndromes and acquired aplastic anemia. In this study, we examined the bone marrow of patients with chronic myeloid leukemia (n = 33, mean age 49 years, age range 2-83 years) for the presence of hematogones and compared their frequency with that of age-matched controls (n = 50). We found that the percentages of total and stage I hematogones were decreased in chronic myeloid leukemia at diagnosis (n = 25) and at follow-up post therapy (n = 8) when compared to age-matched controls (diagnosis, total: 0.29% vs. 0.87%, p = 0.001; diagnosis, stage I: 0.06% vs. 0.20%, p = 0.008; follow-up, total: 0.17% vs. 0.87%, p < 0.001; follow-up, stage I: 0.04 vs. 0.20, p = 0.003). We also found a significant decrease in the number of natural killer cells in patients with chronic myeloid leukemia at diagnosis. Further studies are warranted to elucidate the mechanism of hematogone decrease in chronic myeloid leukemia and whether this finding also applies to other myeloproliferative neoplasms.
